Antimicrobial Stewardship Reduces MDRO Isolates in Critically Ill Patients
NCT02128399 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 978
Last updated 2014-05-01
Summary
Antimicrobial exposure is known to reduce the selection for various drug-resistant organisms. Numerous studies have demonstrated the association between antimicrobial use and MDR bacteria detection. However, to the investigators knowledge, there is few data to support the concept that reducing antibiotic use actually leads to improvements in antibiotic susceptibilities. Moreover, antimicrobial stewardship was demonstrated to reduce MDRO and was strongly recommended in clinics. As the investigators know, antimicrobial overuse, which occurs commonly in China, induces a severe antibacterial resistance. China's Ministry of Health (MOH) has established a policy about the antimicrobial stewardship. To date, the investigators do not have published documentation the effects of this policy on multidrug-resistant organism (MDRO) in critically ill patients.
Conditions
Sponsors & Collaborators
-
Jianfeng Xie
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-06-30
- Primary Completion
- 2013-05-31
- Completion
- 2013-12-31
More Related Trials
-
Therapeutic Drug Monitoring in Patients With Difficult-to-Treat Gram-Negative Bacterial Infections
NCT05942157 ·Status: RECRUITING ·Phase: NA
-
Different Dosing Strategies of Colistin in Multidrug-Resistant Gram-Negative Bacilli Infections
NCT06843668 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Comparison of Solid Organ Transplant
NCT04055922 ·Status: UNKNOWN
-
Therapeutic Drug Monitoring of Anti-infectious Drugs in Intensive Care Unit
NCT03339869 ·Status: UNKNOWN ·Phase: NA
-
Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
NCT05094154 ·Status: COMPLETED ·Phase: PHASE4
-
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
NCT05210387 ·Status: TERMINATED ·Phase: NA
-
ICU-acquired Colonization and Infection Related to MDR in Immunocompromised Patients
NCT04043793 ·Status: COMPLETED
-
Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa Bacteraemia
NCT05210439 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Personalized Optimization of Antibiotic Therapy in Pulmonary Sepsis Critically Ill Patients Through Application of Rapid Microbiological Diagnostic Technologies and Pharmacokinetic/Pharmacodynamic Modelling
NCT06956053 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
PREdiction of CEphalosporinase Producing Enterobacteria During Ventilator-associated Pneumonia for Therapeutic Stewardship
NCT05486130 ·Status: UNKNOWN
-
Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid
NCT03309657 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pharmacokinetics of Antibiotics in Critically Ill Patients Receiving CVVHF
NCT04800952 ·Status: UNKNOWN ·Phase: NA
-
Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria
NCT02134106 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness
NCT03005145 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit
NCT05696093 ·Status: RECRUITING ·Phase: PHASE3
-
Tolerance and Efficacy of Amiklin Administration During Nosocomial Infections Complicating COVID-19 in the ICU
NCT05511129 ·Status: UNKNOWN
-
Risk Factors for Multidrug Resistant Bacteria at ICU Admission
NCT05983861 ·Status: UNKNOWN
-
Rapid Detection of Bacterial Resistance by MALDI-TOF MS and Antibiotic Savings
NCT02860247 ·Status: COMPLETED
-
Antibiotic Treatment Duration (7 vs 14 Days) Comparison in Blood Stream Infection Causes by Enterobacteriaceae
NCT02400268 ·Status: COMPLETED ·Phase: PHASE3
-
Real-world Daptomycin Use in Chinese ICUs
NCT03588637 ·Status: COMPLETED
-
Concentration Monitoring of Anti-infective Drugs in Human Cerebrospinal Fluid and Its Clinical Application
NCT06729619 ·Status: ACTIVE_NOT_RECRUITING
-
Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections
NCT03510351 ·Status: COMPLETED
-
Evaluation of Pharmacokinetic / Pharmacodynamic Data and Interest Individualized Therapeutic Drug Monitoring Glycopeptides and β-lactam-aminoglycoside ICU
NCT02846298 ·Status: UNKNOWN
-
Epidemiological Characteristics and Treatment Protocol for Carbapenem-Resistant Klebsiella Pneumoniae in China
NCT03245632 ·Status: UNKNOWN
-
Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin
NCT02443064 ·Status: UNKNOWN ·Phase: PHASE4